featured emocha Health’s $6.2 million Series A funding round, which will help the company expand its tech-enabled medication adherence service with health plans and transplant centers. emocha’s trajectory, from a spin out of Johns Hopkins in 2014, “shows a path for technology coming out of Baltimore’s medical institutions to become one of the city’s growth software companies.” Initially focused in the public health and infectious disease space, emocha has expanded its scope to chronic diseases like diabetes and asthma. “The same success that we were able to achieve with the infectious diseases, we’ve proven it in asthma, diabetes, and solid organ transplant,” emocha CEO Sebastian Seiguer said. “Now that we have data, successful customers and pilots, we have to go to market.”

Read the full article in